Similarly, CD133+ pancreatic CSCs have been demonstrated to be exclusively tumorigenic and highly resistant to chemotherapy and radiation therapy, and the CD133+ CXCR4+ sub-population of pancreatic CSCs is critical for tumor metastasis,12, 13, 14 suggesting that CSCs have important roles in pancreatic cancer progression. The gene discussed is PROM1; the disease is pancreatic neoplasm.